About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 238284, 9 pages
http://dx.doi.org/10.1155/2013/238284
Research Article

Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer

1Translational Research Group, University Hospital Zurich, 8091 Zurich, Switzerland
2Ovarian Cancer Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales and School of Women’s and Children’s Health Clinical School, University of New South Wales, Sydney, NSW 2052, Australia
3Mathematics Institute for Analysis and Applications (MATHAA), EPFL, 1015 Lausanne, Switzerland
4Gynecological Research Group, University Hospital Basel, 4031 Basel, Switzerland
5Institute of Clinical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
6Department of Gynecology, University Hospital Zurich, 8091 Zurich, Switzerland

Received 18 February 2013; Revised 8 May 2013; Accepted 30 May 2013

Academic Editor: David J. Yang

Copyright © 2013 Michelle Buehler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Seeking new biomarkers for epithelial ovarian cancer, the fifth most common cause of death from all cancers in women and the leading cause of death from gynaecological malignancies, we performed a meta-analysis of three independent studies and compared the results in regard to clinicopathological parameters. This analysis revealed that GAS6 was highly expressed in ovarian cancer and therefore was selected as our candidate of choice. GAS6 encodes a secreted protein involved in physiological processes including cell proliferation, chemotaxis, and cell survival. We performed immunohistochemistry on various ovarian cancer tissues and found that GAS6 expression was elevated in tumour tissue samples compared to healthy control samples ( ). In addition, GAS6 expression was also higher in tumours from patients with residual disease compared to those without. Our data propose GAS6 as an independent predictor of poor survival, suggesting GAS6, both on the mRNA and on the protein level, as a potential biomarker for ovarian cancer. In clinical practice, the staining of a tumour biopsy for GAS6 may be useful to assess cancer prognosis and/or to monitor disease progression.